2
|
Caponetti GC, Dave BJ, Perry AM, Smith LM, Jain S, Meyer PN, Bast M, Bierman PJ, Bociek RG, Vose JM, Armitage JO, Aoun P, Fu K, Greiner TC, Chan WC, Sanger WG, Weisenburger DD. Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome. Leuk Lymphoma 2015; 56:3082-9. [PMID: 25827211 DOI: 10.3109/10428194.2015.1034699] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
In this study, we investigated the significance of MYC, BCL2 and BCL6 gene abnormalities in a cohort of 205 diffuse large B-cell lymphoma (DLBCL) patients studied by conventional and/or fluorescence in situ hybridization cytogenetic analysis. Combining these methods, 172 cases (84%) were classified as MYC-, 17 (8%) were MYC+/BCL2-/BCL6-, and 16 (8%) were double/triple-hit lymphomas (i.e. MYC+/BCL2+, MYC+/BCL6+, or MYC+/BCL2+/BCL6+). We found a significant difference in event-free survival (EFS) among the three groups (p = 0.02), with the double/triple-hit group having the worst EFS. Patients who were MYC+, but BCL2- and BCL6-, had the best EFS. We conclude that patients with MYC+ DLBCL, but without BCL2 or BCL6 abnormalities, do not have a worse outcome when compared to those who are MYC-. However, patients with double/triple-hit DLBCL have a very poor outcome and should be treated with aggressive or novel therapies.
Collapse
Affiliation(s)
- Gabriel C Caponetti
- a Department of Pathology , Creighton University Medical Center , Omaha , NE , USA
| | - Bhavana J Dave
- b Human Genetics Laboratory, Munroe Meyer Institute for Genetics and Rehabilitation, University of Nebraska Medical Center , Omaha , NE , USA
| | - Anamarija M Perry
- c Department of Pathology , University of Manitoba , Winnipeg, Manitoba , Canada
| | - Lynette M Smith
- d Department of Biostatistics , University of Nebraska Medical Center , Omaha , NE , USA
| | - Smrati Jain
- b Human Genetics Laboratory, Munroe Meyer Institute for Genetics and Rehabilitation, University of Nebraska Medical Center , Omaha , NE , USA
| | - Paul N Meyer
- e Southern Arizona Veterans Administration Health Care , Tucson , AZ
| | - Martin Bast
- f Internal Medicine, University of Nebraska Medical Center , Omaha , NE , USA
| | - Philip J Bierman
- f Internal Medicine, University of Nebraska Medical Center , Omaha , NE , USA
| | - Robert G Bociek
- f Internal Medicine, University of Nebraska Medical Center , Omaha , NE , USA
| | - Julie M Vose
- f Internal Medicine, University of Nebraska Medical Center , Omaha , NE , USA
| | - James O Armitage
- f Internal Medicine, University of Nebraska Medical Center , Omaha , NE , USA
| | - Patricia Aoun
- g Department of Pathology , City of Hope National Medical Center , Duarte , CA , USA
| | - Kai Fu
- h Pathology and Microbiology, University of Nebraska Medical Center , Omaha , NE , USA
| | - Timothy C Greiner
- h Pathology and Microbiology, University of Nebraska Medical Center , Omaha , NE , USA
| | - Wing C Chan
- g Department of Pathology , City of Hope National Medical Center , Duarte , CA , USA
| | - Warren G Sanger
- b Human Genetics Laboratory, Munroe Meyer Institute for Genetics and Rehabilitation, University of Nebraska Medical Center , Omaha , NE , USA
| | - Dennis D Weisenburger
- g Department of Pathology , City of Hope National Medical Center , Duarte , CA , USA
| |
Collapse
|
3
|
Cytosine arabinoside and mitoxantrone followed by second allogeneic transplant for the treatment of children with refractory juvenile myelomonocytic leukemia. J Pediatr Hematol Oncol 2014; 36:491-4. [PMID: 24322499 PMCID: PMC4048652 DOI: 10.1097/mph.0000000000000077] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Hematopoietic stem cell transplantation (HSCT) remains the only curative option for most patients with juvenile myelomonocytic leukemia (JMML). However, persistent disease and relapse rates after transplant range from 26% to 58%. We report the successful use of second HSCT after preparation with mitoxantrone and cytosine arabinoside (Ara-C) for patients with refractory or recurrent disease. Between 1993 and 2006, 5 children who underwent HSCT at our institution as initial therapy for JMML had persistent disease or relapsed. Pre-HSCT conditioning varied and donors were either HLA-matched siblings (n=2) or matched unrelated donors (n=3). After initial HSCT, they subsequently received high-dose Ara-C (3 g/m IV) every 12 hours on days -8 through -3 and mitoxantrone (10 mg/m/d IV) on days -8, -7, -6 followed by second HSCT from their original donors. All 5 patients are alive at 88, 179, 199, 234, and 246 months with no evidence of JMML, no significant toxicity, and 100% donor chimera as determined by PCR short-tandem repeat analysis. Our experience supports second transplant utilizing high-dose Ara-C and mitoxantrone in children with JMML who do not respond or relapse after first transplant.
Collapse
|
4
|
Hassan HM, Varney ML, Jain S, Weisenburger DD, Singh RK, Dave BJ. Disruption of chromosomal locus 1p36 differentially modulates TAp73 and ΔNp73 expression in follicular lymphoma. Leuk Lymphoma 2014; 55:2924-31. [PMID: 24660851 DOI: 10.3109/10428194.2014.900759] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The TP73 gene is located at the chromosome 1p36 locus that is commonly disrupted or deleted in follicular lymphoma (FL) with poor prognosis. Therefore, we analyzed the expression of the pro-apoptotic TAp73 and anti-apoptotic ΔNp73 isoforms in cases of FL with normal or abnormal 1p36. We observed a significant increase in ΔNp73 expression and ΔNp73:TAp73 ratio, lower expression of cleaved caspase-3 and a higher frequency of Ki-67 and proliferating cell nuclear antigen (PCNA) positive cells in cases of FL with abnormal 1p36. A negative correlation between the ΔNp73:TAp73 ratio and cleaved caspase-3 expression, and a positive correlation between ΔNp73 expression and Ki-67 or PCNA, were observed. The expression of TAp73 and its pro-apoptotic transcriptional targets BIM. PUMA and NOXA were significantly lower in FL compared to reactive follicular hyperplasia. Together, our data demonstrate that 1p36 disruption is associated with increased ΔNp73 expression, decreased apoptosis and increased proliferation in FL.
Collapse
Affiliation(s)
- Hesham M Hassan
- Department of Pathology and Microbiology, University of Nebraska Medical Center , Omaha, NE , USA
| | | | | | | | | | | |
Collapse
|
5
|
Perry AM, Crockett D, Dave BJ, Althof P, Winkler L, Smith LM, Aoun P, Chan WC, Fu K, Greiner TC, Bierman P, Gregory Bociek R, Vose JM, Armitage JO, Weisenburger DD. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases. Br J Haematol 2013; 162:40-9. [DOI: 10.1111/bjh.12343] [Citation(s) in RCA: 67] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2013] [Accepted: 03/04/2013] [Indexed: 11/30/2022]
Affiliation(s)
| | - David Crockett
- Department of Internal Medicine; University of Nebraska Medical Center; Omaha; NE; USA
| | - Bhavana J. Dave
- Human Genetics Laboratory; Munroe-Meyer Institute; University of Nebraska Medical Center; Omaha; NE; USA
| | - Pamela Althof
- Human Genetics Laboratory; Munroe-Meyer Institute; University of Nebraska Medical Center; Omaha; NE; USA
| | - Lisa Winkler
- Human Genetics Laboratory; Munroe-Meyer Institute; University of Nebraska Medical Center; Omaha; NE; USA
| | - Lynette M. Smith
- Department of Biostatistics; University of Nebraska Medical Center; Omaha; NE; USA
| | - Patricia Aoun
- Department of Pathology; City of Hope National Medical Center; Duarte; CA; USA
| | - Wing C. Chan
- Department of Pathology and Microbiology; University of Nebraska Medical Center; Omaha; NE; USA
| | - Kai Fu
- Department of Pathology and Microbiology; University of Nebraska Medical Center; Omaha; NE; USA
| | - Timothy C. Greiner
- Department of Pathology and Microbiology; University of Nebraska Medical Center; Omaha; NE; USA
| | - Phillip Bierman
- Department of Internal Medicine; University of Nebraska Medical Center; Omaha; NE; USA
| | - Robert Gregory Bociek
- Department of Internal Medicine; University of Nebraska Medical Center; Omaha; NE; USA
| | - Julie M. Vose
- Department of Internal Medicine; University of Nebraska Medical Center; Omaha; NE; USA
| | - James O. Armitage
- Department of Internal Medicine; University of Nebraska Medical Center; Omaha; NE; USA
| | | |
Collapse
|
7
|
Ahrens AK, Chaturvedi NK, Nordgren TM, Dave BJ, Joshi SS. Establishment and characterization of therapy-resistant mantle cell lymphoma cell lines derived from different tissue sites. Leuk Lymphoma 2012; 53:2269-78. [PMID: 22568512 DOI: 10.3109/10428194.2012.691481] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Mantle cell lymphoma (MCL) is a rare but aggressive form of B cell non-Hodgkin lymphoma in which therapy resistance is common. New therapeutic options have extended survival in refractory MCL but have not provided durable remission. Tools are needed to assess the molecular and genetic changes associated with therapy resistance. Therefore, therapy-resistant MCL cell lines were established from the liver, kidney and lungs of human Granta 519-bearing NOD-SCID (non-obese diabetic-severe combined immunodeficiency) mice following treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy in combination with bortezomib. The cytomorphologies, immunophenotypes, growth patterns in semi-solid agar, cytogenetic profiles and gene expression differences between these cell lines were characterized to identify major changes associated with therapy resistance. Therapy-resistant cell lines exhibit more aggressive growth patterns and markedly different gene expression profiles compared to parental Granta 519 cells. Thus, these stable therapy-resistant cell lines are useful models to further study the molecular basis of drug resistance and to identify clinically relevant molecular targets in MCL.
Collapse
Affiliation(s)
- Adam K Ahrens
- Department of Genetics, University of Nebraska Medical Center, Omaha, NE, USA
| | | | | | | | | |
Collapse
|